The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Lexicon; Lexicon; Lexicon; Lexicon
Stock and Other Ownership Interests - Lexicon; Lexicon; Lexicon; Lexicon
Exploring telotristat ethyl’s antiproliferative effects in patients with carcinoid syndrome (TELEACE): A real-world observational study.
 
Michael Morse
Stock and Other Ownership Interests - PhytoChem; PhytoChem; PhytoChem; PhytoChem
Honoraria - Bayer; Bayer; Bayer; Bayer; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Eisai; Eisai; Eisai; Eisai; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Etubics; Etubics; Etubics; Etubics; Exelixis; Exelixis; Exelixis; Exelixis; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Ipsen; Ipsen; Ipsen; Ipsen; Lexicon; Lexicon; Lexicon; Lexicon; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Merrimack; Merrimack; Merrimack; Merrimack; Novartis; Novartis; Novartis; Novartis; Onyx; Onyx; Onyx; Onyx; Regeneron; Regeneron; Regeneron; Regeneron; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Speakers' Bureau - Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Celgene; Celgene; Celgene; Celgene; Eisai; Eisai; Eisai; Eisai; Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Ipsen; Ipsen; Ipsen; Ipsen; Lexicon; Lexicon; Lexicon; Lexicon; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); AlphaVax (Inst); AlphaVax (Inst); AlphaVax (Inst); AlphaVax (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Lexicon (Inst); Lexicon (Inst); Lexicon (Inst); Lexicon (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Onyx (Inst); Onyx (Inst); Onyx (Inst); Onyx (Inst); Precision Biologics (Inst); Precision Biologics (Inst); Precision Biologics (Inst); Precision Biologics (Inst)
Patents, Royalties, Other Intellectual Property - Compositions And Methods For Modulating And Redirecting Immune Responses Publication number: 20170015758 Inventors: Scott A. HAMMOND, Michael A. MORSE, Takuya OSADA, Herbert Kim LYERLY; Compositions And Methods For Modulating And Redirecting Immune Responses Publication number: 20170015758 Inventors: Scott A. HAMMOND, Michael A. MORSE, Takuya OSADA, Herbert Kim LYERLY; Compositions And Methods For Modulating And Redirecting Immune Responses Publication number: 20170015758 Inventors: Scott A. HAMMOND, Michael A. MORSE, Takuya OSADA, Herbert Kim LYERLY; Compositions And Methods For Modulating And Redirecting Immune Responses Publication number: 20170015758 Inventors: Scott A. HAMMOND, Michael A. MORSE, Takuya OSADA, Herbert Kim LYERLY; PHARMACEUTICAL PRODUCT, MEDICAL FOOD OR DIETARY SUPPLEMENT FOR PREVENTING CANCER AND INFLAMMATORY DISEASES Publication number: 20170246136 Applicant: OliVentures, Inc. Inventors: Carlos María Peña Díaz, Guillermo Muñoz Fernández, Michael Morse; PHARMACEUTICAL PRODUCT, MEDICAL FOOD OR DIETARY SUPPLEMENT FOR PREVENTING CANCER AND INFLAMMATORY DISEASES Publication number: 20170246136 Applicant: OliVentures, Inc. Inventors: Carlos María Peña Díaz, Guillermo Muñoz Fernández, Michael Morse; PHARMACEUTICAL PRODUCT, MEDICAL FOOD OR DIETARY SUPPLEMENT FOR PREVENTING CANCER AND INFLAMMATORY DISEASES Publication number: 20170246136 Applicant: OliVentures, Inc. Inventors: Carlos María Peña Díaz, Guillermo Muñoz Fernández, Michael Morse; PHARMACEUTICAL PRODUCT, MEDICAL FOOD OR DIETARY SUPPLEMENT FOR PREVENTING CANCER AND INFLAMMATORY DISEASES Publication number: 20170246136 Applicant: OliVentures, Inc. Inventors: Carlos María Peña Díaz, Guillermo Muñoz Fernández, Michael Morse; Vaccines against antigens involved in therapy resistance and methods of using same Patent number: 9956276 Assignee Duke University; Vaccines against antigens involved in therapy resistance and methods of using same Patent number: 9956276 Assignee Duke University; Vaccines against antigens involved in therapy resistance and methods of using same Patent number: 9956276 Assignee Duke University; Vaccines against antigens involved in therapy resistance and methods of using same Patent number: 9956276 Assignee Duke University
 
Eric Liu
Consulting or Advisory Role - Lexicon; Lexicon; Lexicon; Lexicon
 
Vijay N. Joish
Employment - Lexicon; Lexicon; Lexicon; Lexicon
Stock and Other Ownership Interests - Lexicon; Lexicon; Lexicon; Lexicon
 
Lynn Huynh
Research Funding - Lexicon (Inst); Lexicon (Inst); Lexicon (Inst); Lexicon (Inst)
 
Mu Cheng
Research Funding - Lexicon (Inst); Lexicon (Inst); Lexicon (Inst); Lexicon (Inst)
 
Todor Totev
Research Funding - California Institute for Regenerative Medicine (CIRM) (Inst); California Institute for Regenerative Medicine (CIRM) (Inst); California Institute for Regenerative Medicine (CIRM) (Inst); California Institute for Regenerative Medicine (CIRM) (Inst); Epizyme (Inst); Epizyme (Inst); Epizyme (Inst); Epizyme (Inst); Kiniksa (Inst); Kiniksa (Inst); Kiniksa (Inst); Kiniksa (Inst); Lexicon (Inst); Lexicon (Inst); Lexicon (Inst); Lexicon (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Mei S. Duh
Research Funding - Lexicon (Inst); Lexicon (Inst); Lexicon (Inst); Lexicon (Inst)
 
Pablo Lapuerta
No Relationships to Disclose
 
David C. Metz
Consulting or Advisory Role - Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; lexicon; lexicon; lexicon; lexicon; wren laboratories; wren laboratories; wren laboratories; wren laboratories
Research Funding - Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; lexicon; lexicon; lexicon; lexicon; wren laboratories; wren laboratories; wren laboratories; wren laboratories
Expert Testimony - Mylan; Mylan; Mylan; Mylan